Evidence mapPaperPMID 31903769Full record

ArticleJournal of diabetes science and technology2020

The Need for Precision Medicine to be Applied to Diabetes.

David C Klonoff, Jose C Florez, Michael German, Alexander Fleming

Open access · bronzeAbstract read
In one paragraph

Article in Journal of diabetes science and technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Precision oncology: transforming cancer care through personalized medicine.Medical oncology (Northwood, London, England) · 2025
    Review
  2. Article
  3. Article
  4. Digital Connectivity: The Sixth Vital Sign.Journal of diabetes science and technology · 2022
    Article
  5. Rapid Point-of-Care Test for Determination of C-Peptide Levels.Journal of diabetes science and technology · 2022
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

David C KlonoffDiabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, CA, USA.
Jose C FlorezDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
Michael GermanDepartment of Medicine, University of California San Francisco, CA, USA.
Alexander FlemingKinexum, Harpers Ferry, WV, USA.
Broad Center · USHarper College · USHarvard University · USMills Peninsula Health Services · US

Funding

PILOT &FEASIBILTY 2P30DK063720 · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · 2003 to 2005
$3.6M
NIDDK NIH HHS P30 DK063720
6 · The paper itself

Abstract

Precision medicine refers to the tailoring of medical treatment for an individual based on large amounts of biologic and extrinsic data. The fast advancing fields of molecular biology, gene sequencing, machine learning, and other technologies enable precision medicine to utilize this detailed information to enhance clinical management decision-making for an individual in the real time of the disease course. Traditional clinical decision making is based on reacting to a relatively limited number of phenotypes that are determined by history, physical examination, and conventional lab tests. Precision medicine depends on highly detailed profiling of the patient's genetic, morphologic, and metabolic makeup. The precision medicine approach can be applied to individuals with diabetes to select treatments most likely to offer benefit and least likely to cause side effects, offering prospects of improved clinical outcomes and economic costs savings over current empiric practices. As genetic, metabolomic, immunologic, and other sophisticated testing becomes less expensive and more widespread in the medical record, it is expected that precision medicine will become increasingly applied to diabetes care.

Indexed as

GenomicsPharmacogeneticsPrecision MedicineBiomarkersBlood GlucoseClinical Decision-MakingDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Genetic Predisposition to DiseaseHumansHypoglycemic AgentsPatient SelectionPharmacogenomic VariantsPhenotypeTreatment OutcomeBiomarkersBlood GlucoseHypoglycemic Agentsdiabetesgenesomicspharmacogeneticsphenotypeprecision medicine

Identifiers

PMID31903769
PMCPMC7645141
OpenAlexW2997493014

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.